Modulation of the development of human monocyte-derived dendritic cells by lithium chloride

Journal of Cellular Physiology

Volumn 226, Issue 2, 2011, Pages 424-433

  Liu, Ko Jiunn ^a,b   Lee, Yueh Lun ^b   Yang, Yi Yuan ^b,c   Shih, Neng Yao ^a   Ho, Chia Chen ^b   Wu, Yu Chen ^a   Huang, Tze Sing ^a   Huang, Ming Chyi ^b,d,e   Liu, Hsing Cheng ^d,e   Shen, Winston W ^e   Leu, Sy Jye ^b,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI CITY HOSPITAL   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD1 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LITHIUM CHLORIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN ERK; PROTEIN KINASE B; PROTEIN MEK; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MODULATION; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD; ANTIGENS, CD86; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOGLOBULINS; INTERLEUKINS; LITHIUM CHLORIDE; MEMBRANE GLYCOPROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MONOCYTES; PHOSPHATIDYLINOSITOL 3-KINASES; PPAR GAMMA; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649641162     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22348     Document Type: Article

References (56)

1. Banchereau J, Steinman RM. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
2. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. 2000. Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811.
3. Battistini L, Fischer FR, Raine CS, Brosnan CF. 1996. CD1b is expressed in multiple sclerosis lesions. J Neuroimmunol 67: 145-151.
4. Boufidou F, Nikolaou C, Alevizos B, Liappas IA, Christodoulou GN. 2004. Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord 82: 309-313.
5. Breunis MN, Kupka RW, Nolen WA, Suppes T, Denicoff KD, Leverich GS, Post RM, Drexhage HA. 2003. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry 53: 157-165.
6. Bricard G, Porcelli SA. 2007. Antigen presentation by CD1 molecules and the generation of lipid-specific T cell immunity. Cell Mol Life Sci 64: 1824-1840.
7. Calabrese JR, Shelton MD, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, Ganocy SJ, Findling RL. 2005. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 162: 2152-2161.
8. Chalecka-Franaszek E, Chuang DM. 1999. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 96: 8745-8750.
9. Chen KP, Shen WW, Lu ML. 2004. Implication of serum concentration monitoring in patients with lithium intoxication. Psychiatry Clin Neurosci 58: 25-29.
10. Chuang DM. 2004. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: Can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 16: 83-90.
11. Chuang DM, Priller J. 2006. Potential use of lithium in neurodegenerative disorders. In: Bauer M, Grof P, Muller-Oerlinghausen B, editors. Lithium in neuropsychiatry: The comprehensive guide. London, UK: Informa Healthcare. pp. 381-397.
12. De Sarno P, Li X, Jope RS. 2002. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43: 1158-1164.
13. De Sarno P, Axtell R, Raman C, Roth KA, Alessi DR, Jope RS. 2008. Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J Immunol 181: 338-345.
14. Feyt C, Kienlen-Campard P, Leroy K, N'Kuli F, Courtoy PJ, Brion JP, Octave JN. 2005. Lithium chloride increases the production of amyloid-beta peptide independently from its inhibition of glycogen synthase kinase 3. J Biol Chem 280: 33220-33227.
15. Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK. 2004. Emerging experimental therapeutics for bipolar disorder: Insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 9: 734-755.
16. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC. 2003. Dendritic cell function in vivo during the steady state: A role in peripheral tolerance. Ann NY Acad Sci 987: 15-25.
17. Jope RS. 2003. Lithium and GSK-3: One inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24: 441-443.
18. Khalili-Shirazi A, Gregson NA, Londei M, Summers L, Hughes RA. 1998. The distribution of CD1 molecules in inflammatory neuropathy. J Neurol Sci 158: 154-163.
19. Kim JW, Kim SY, Park SY, Kim YM, Kim JM, Lee MH, Ryu HM. 2004a. Mesenchymal progenitor cells in the human umbilical cord. Ann Hematol 83: 733-738.
20. Kim YK, Myint AM, Lee BH, Han CS, Lee SW, Leonard BE, Steinbusch HW. 2004b. T-helper types 1, 2 and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res 129: 267-272.
21. Kim Y-K, Jung H-G, Myint A-M, Kim H, Park S-H. 2007. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 104: 91-95; Epub 2007 Apr 2016.
22. Klein PS, Melton DA. 1996. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93: 8455-8459.
23. Knijff EM, Ruwhof C, de Wit HJ, Kupka RW, Vonk R, Akkerhuis GW, Nolen WA, Drexhage HA. 2006. Monocyte-derived dendritic cells in bipolar disorder. Biol Psychiatry 59: 317-326.
24. Kopnisky KL, Chalecka-Franaszek E, Gonzalez-Zulueta M, Chuang DM. 2003. Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities. Neuroscience 116: 425-435.
25. Kupka RW, Nolen WA, Post RM, McElroy SL, Altshuler LL, Denicoff KD, Frye MA, Keck PE, Jr., Leverich GS, Rush AJ, Suppes T, Pollio C, Drexhage HA. 2002. High rate of autoimmune thyroiditis in bipolar disorder: Lack of association with lithium exposure. Biol Psychiatry 51: 305-311.
26. Lauterbach E, Felber W, Muller-Oerlinghausen B, Ahrens B, Bronisch T, Meyer T, Kilb B, Lewitzka U, Hawellek B, Quante A, Richter K, Broocks A, Hohagen F. 2008. Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: A randomised, placebo-controlled, 1-year trial. Acta Psychiatr Scand 118: 469-479.
27. Lenox RH, Hahn CG. 2000. Overview of the mechanism of action of lithium in the brain: Fifty-year update. J Clin Psychiatry 61: 5-15.
28. Liu J, Farmer SR. 2004. Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem 279: 45020-45027.
29. Lovestone S, Davis DR, Webster MT, Kaech S, Brion JP, Matus A, Anderton BH. 1999. Lithium reduces tau phosphorylation: Effects in living cells and in neurons at therapeutic concentrations. Biol Psychiatry 45: 995-1003.
30. Martin M, Rehani K, Jope RS, Michalek SM. 2005. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6: 777-784; Epub 2005 Jul 2010.
31. Matsuyama M, Yoshimura R. 2008. Peroxisome proliferator-activated receptor-gamma is a potent target for prevention and treatment in human prostate and testicular cancer. PPAR Res 2008: 249849.
32. Moscovich DG. 1993. Lithium neurotoxicity at normal therapeutic levels. Br J Psychiatry 163: 410-412.
33. Munoz-Montano JR, Moreno FJ, Avila J, Diaz-Nido J. 1997. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett 411: 183-188.
34. Nagappan R, Parkin WG, Holdsworth SR. 2002. Acute lithium intoxication. Anaesth Intensive Care 30: 90-92.
35. Ortiz-Dominguez A, Hernandez ME, Berlanga C, Gutierrez-Mora D, Moreno J, Heinze G, Pavon L. 2007. Immune variations in bipolar disorder: Phasic differences. Bipolar Disord 9: 596-602.
36. Palucka K, Banchereau J. 1999a. Dendritic cells: A link between innate and adaptive immunity. J Clin Immunol 19: 12-25.
37. Palucka K, Banchereau J. 1999b. Linking innate and adaptive immunity. Nat Med 5: 868-870.
38. Pilcher HR. 2003. Drug research: The ups and downs of lithium. Nature 425: 118-120.
39. Price LH, Heninger GR. 1994. Lithium in the treatment of mood disorders. N Engl J Med 331: 591-598.
40. Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C. 2001. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 22: 41-47.
41. Rodionova E, Conzelmann M, Maraskovsky E, Hess M, Kirsch M, Giese T, Ho AD, Zoller M, Dreger P, Luft T. 2007. GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood 109: 1584-1592.
42. Rossi M, Young JW. 2005. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol 175: 1373-1381.
43. Rowe MK, Chuang DM. 2004. Lithium neuroprotection: Molecular mechanisms and clinical implications. Expert Rev Mol Med 6: 1-18.
44. Sallusto F, Lanzavecchia A. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179: 1109-1118.
45. Shen WW, Liu HC, Yang YY, Lin CY, Chen KP, Yeh TS, Leu SJ. 2006. Anti-heat shock protein 90 is increased in acute mania. Aust NZ J Psychiatry 40: 712-716.
46. Speirs J, Hirsch SR. 1978. Severe lithium toxicity with "normal" serum concentrations. Br Med J 1: 815-816.
47. Steinman RM, Hawiger D, Liu K, Bonifaz L, Bonnyay D, Mahnke K, Iyoda T, Ravetch J, Dhodapkar M, Inaba K, Nussenzweig M. 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194: 769-779.
48. Szatmari I, Gogolak P, Im JS, Dezso B, Rajnavolgyi E, Nagy L. 2004. Activation of PPARgamma specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion. Immunity 21: 95-106.
49. Szatmari I, Torocsik D, Agostini M, Nagy T, Gurnell M, Barta E, Chatterjee K, Nagy L. 2007. PPAR{gamma} regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 110: 3271-3280.
50. Tontonoz P, Hu E, Spiegelman BM. 1995. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev 5: 571-576.
51. Tsai SY, Chen KP, Yang YY, Chen CC, Lee JC, Singh VK, Leu SJ. 1999. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry 45: 989-994.
52. Vines A, Cahoon S, Goldberg I, Saxena U, Pillarisetti S. 2006. Novel anti-inflammatory role for glycogen synthase kinase-3beta in the inhibition of tumor necrosis factor-alpha- and interleukin-1beta-induced inflammatory gene expression. J Biol Chem 281: 16985-16990; Epub 12006 Apr 16986.
53. Webb AL, Solomon DA, Ryan CE. 2001. Lithium levels and toxicity among hospitalized patients. Psychiatr Serv 52: 229-231.
54. Xie J, Qian J, Yang J, Wang S, Freeman ME III, Yi Q. 2005. Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells. Exp Hematol 33: 564-572.
55. Zajonc DM, Kronenberg M. 2007. CD1 mediated T cell recognition of glycolipids. Curr Opin Struct Biol 17: 521-529.
56. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS. 2003. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 278: 33067-33077.